Cipla and Glenmark initiate recall of certain products in the US

2024-05-06
Pharmaceutical Technology
上市批准
Cipla and Glenmark initiate recall of certain products in the US
Preview
来源: Pharmaceutical Technology
Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is prescribed for controlling the symptoms of lung diseases. Credit: mi_viri / Shutterstock.com.
Cipla and Glenmark Pharmaceuticals are recalling specific products from the US market due to distinct manufacturing issues, the latest Enforcement Report issued by the US Food and Drug Administration (USFDA) noted.
The recalls involve inhalation solutions and extended-release capsules used for treating respiratory conditions and high blood pressure, respectively.
New Jersey-based subsidiary of Cipla, Cipla USA is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution.
This product is manufactured at Indore SEZ plant of the company in India.
It is prescribed for controlling the symptoms of lung diseases such as chronic bronchitis, asthma, and emphysema.
See Also:Pacira BioSciences gets grant for method for treating spasticity in a patient’s limb using cryogenic cooling
Cipla and Glenmark initiate recall of certain products in the US
Preview
来源: Pharmaceutical Technology
Axsome Therapeutics gets grant for treating narcolepsy with cataplexy using reboxetine
Cipla and Glenmark initiate recall of certain products in the US
Preview
来源: Pharmaceutical Technology
The recall of the affected inhalation solution lot is claimed to be due to complaints of “short fill”.
The US regulator detailed that the affected lot was recalled after reports of less fill volume in respules and the presence of a few drops of liquid in the intact pouch.
Simultaneously, Glenmark Pharmaceuticals, USA, the US-based arm of Glenmark, announced the recall of 3,264 Diltiazem Hydrochloride extended-release capsules bottles.
The medication, intended for high blood pressure treatment, was recalled due to “failed dissolution specifications”.
In a related event last month, Glenmark’s US unit recalled 6,528 bottles of Diltiazem Hydrochloride extended-release capsules.
This Class II recall was due to the medication not meeting dissolution specifications, with “Out of Specification (OOS) results in a dissolution test at the 12-month time point during a long-term stability study.”
The affected lot was also produced in India.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。